What are “3 Key Trends” shaping the CDMO industry in 2022 and beyond? Adare Pharma Solutions’ Vice President and Head of North America Business Development, Ulrike (Uli) Foley, shares her thoughts with Contract Pharma.

Patient centric dosage formulations for pediatrics and geriatrics

One of the biggest challenges in treatment regimen of acute or chronic conditions is patient acceptance and adherence to prescribed therapeutic dosing; particularly special patient populations (pediatrics and geriatrics). Beyond the burden imposed on the healthcare system—including patients and caregivers—non-adherence often undermines the safety and efficacy of the therapeutics, leading to poor therapeutic outcomes. Among other factors, palatability and swallowability of oral medications significantly influence therapeutic regimen acceptance and adherence by patients.

Adare’s dosage formulation technologies offer an increased palatability and acceptance of dosing. Adare’s Microcaps and Optimµm technologies can each effectively mask the unpleasant and bitter tastes of medications and provide customizable drug release to improve patient acceptance and adherence. Microcaps and Optimµm technology platforms can each produce intermediate taste-masked microparticles that can be incorporated into patient-centric dosage forms (liquid suspension, ODT, chewable, dispersible or powder) for ease of administration.

Long-acting injections: Size matters

Long-acting injection (LAI) products are an important clinical therapeutic approach that improve therapeutic outcomes by enhancing patient compliance to therapeutic regimens. LAI antipsychotics are an important therapeutic option in treating schizophrenia. Use of LAIs is expanding to other important therapeutic areas such as diabetes and HIV. Patient self-administration becomes a consideration as the use of LAIs expands to include chronic conditions.

Here it turns out that the size of the long-acting injectable microspheres matters if patient self-administration with small needle gauge autoinjectors is desired. Traditional methods of producing long-acting microspheres result in formulations containing microparticles of broad particle size distributions that clog autoinjector needles. Long-acting injectable microspheres produced by Adare Pharma Solutions’ Stratµm technology have a narrow size distribution profile that allow for the use of autoinjectors.

End-to-end solutions: De-risking and consolidation with fewer partners

With pharmaceutical industry trends like targeted therapies, high potency APIs, controlled substances, globalization (with differing global regulatory demands) and diversified pipelines, new challenges are being presented to the traditional CDMO/CMO industry. Companies like Adare Pharma Solutions are actively altering the traditional CDMO/CMO business model, adding capabilities that simplify, de-risk and consolidate clients’ needs under one roof. Adare Pharma Solutions has recently acquired Frontida Biopharm, expanding to over 800 employees and a global footprint of 7 facilities, capable of handling high potency APIs, controlled substances, packaging and global regulatory regimes.

---

Adare Pharma Solutions is a leading partner to over 100 pharmaceutical companies for NCEs, NDAs, ANDAs, 505(b)(2)s, specialty pharma, OTC products and more. Adare’s drug delivery technology portfolio can offer improved palatability, optimized therapeutic performance, improved solubility and patient adherence.